Teva Recalls Mefloquine Hydrochloride Tablets Due to Weight Variations
Teva Pharmaceuticals is recalling Mefloquine Hydrochloride 250 mg tablets because they may be underweight or overweight.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 2/5 (Moderate).
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II, and the hazard involves potential weight variations (underweight or overweight) which may affect dosing accuracy but are not explicitly linked to reported serious injuries or deaths in the source text.
Plain-English summary
Teva Pharmaceuticals USA, Inc. is recalling Mefloquine Hydrochloride 250 mg tablets. The recall is due to the potential for the tablets to be underweight or overweight.
The affected product is identified by Lot # 34000741A with an expiration date of 7/2013. The product is distributed nationwide in cartons containing 25 unit-dose tablets (5 blister packs of 5 tablets each). The recall involves 4,188 cartons.
Consumers should check their medication for the specific lot number and expiration date. If the product matches the recalled lot, they should contact their healthcare provider or pharmacist for guidance on disposal or replacement.
The recalled product
- Product
- MEFLOQUINE HYDROCHLORIDE (MEFLOQUINE HYDROCHLORIDE)
- Brand
- MEFLOQUINE HYDROCHLORIDE
- Manufacturer
- Teva Pharmaceuticals USA, Inc.
- Category
- Drug — Antimalarial
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot # 34000741A
- Expiration date: 7/2013
Distribution
Distributed nationwide across the United States.
Related recalls
Same manufacturer · Teva Pharmaceuticals USA, Inc.
See all →- SevereTeva Recalls Trazodone Hydrochloride Tablets Due to Foreign Material
FDA (Drugs) · 2026-09-09
- SevereOctreotide Acetate Injectable Suspension Recalled Due to Sterility Assurance
FDA (Drugs) · 2026-05-13
- ModerateClaravis isotretinoin 10 mg capsules recalled for out-of-specification impurity
FDA (Drugs) · 2026-04-29
- ModerateTeva clonidine 0.3 mg patches recalled over unapproved raw material use
FDA (Drugs) · 2026-04-15
- HighTeva isotretinoin 40 mg capsules recalled as superpotent and subpotent
FDA (Drugs) · 2026-04-15
Same hazard · dosage variation
See all →- SevereActavis Recalls Alprazolam Tablets Due to Weight Specification Failures
FDA (Drugs) · 2013-12-04
Similar recalls
- ModerateTeva Recalls Methylphenidate Hydrochloride Extended-Release Tablets Due to Missing Desiccant
FDA (Drugs) · 2020-02-19
- ModerateTeva Recalls Methylphenidate Hydrochloride Capsules Due to Dissolution Failures
FDA (Drugs) · 2013-08-14
- ModerateTeva Recalls Methylphenidate Hydrochloride Extended-Release Capsules Due to Dissolution Failure
FDA (Drugs) · 2013-08-14
- ModerateTeva Recalls Methylphenidate Hydrochloride Capsules for Dissolution Failures
FDA (Drugs) · 2013-08-14
- ModerateTeva Recalls Famotidine Tablets Due to Weight Specification Failures
FDA (Drugs) · 2017-08-09
- HighTeva Amphetamine Tablets Recalled Due To Incorrect Strength Labeling
FDA (Drugs) · 2022-09-21